Primary Lower Extremity Telangiectasias -- Relationship of Size to Color

Biegeleisen, Ken
October 1987
Angiology;Oct1987, Vol. 38 Issue 10, p760
Academic Journal
Sclerotherapy remains the treatment of choice for primary telangiectasias of the lower extremities, a half century after the treatment was first devised. No substantial improvements have been made, largely because little or no attention has been paid to the underlying physiology. Evidence is presented that these vessels are dilated by virtue of their proximity to small arteriovenous communications. This would explain the response these vessels demonstrate when injected with sclerosing solutions, as well as the relationship between their size and their color, which is documented by objective and subjective measurements. Two novel methods of treating telangiectasias with existing sclerosing solutions are described, and the characteristics of an ideal sclerosant for these vessels are proposed.


Related Articles

  • A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. Pierucci, Paola; Lenato, Gennaro M.; Suppressa, Patrizia; Lastella, Patrizia; Triggiani, Vincenzo; Valerio, Raffaella; Comelli, Mario; Salvante, Daniela; Stella, Alessandro; Resta, Nicoletta; Logroscino, Giancarlo; Resta, Francesco; Sabb�, Carlo // Orphanet Journal of Rare Diseases;2012, Vol. 7 Issue 1, p33 

    Background: The difficulty in establishing a timely correct diagnosis is a relevant matter of concern for several rare diseases. Many rare-disease-affected patients suffer from considerable diagnostic delay, mainly due to their poor knowledge among healthcare professionals, insufficient disease...

  • Symptomatic capillary telangiectasia of the pons: three pediatric cases diagnosed by suspectibility-weighted imaging. Orgun, Leman; Arhan, Ebru; Aydın, Kursad; Serdaroglu, Ayse; Gücüyener, Kıvılcım // Child's Nervous System;Nov2016, Vol. 32 Issue 11, p2261 

    Introduction: Brain capillary telangiectasias (BCT) are small, clinically benign, usually asymptomatic and rarely seen lesions during childhood. Large symptomatic BCT during childhood are extremely rare, with only a few reports in the literature. They usually cannot be detected easily on...

  • Anaesthetic management of a patient with Osler-Weber-Rendu's syndrome posted for Young's procedure. Bhalerao, Pradnya M.; Pandit, Savita C.; Swati, V. C.; Jadhawar, Suraj T. // Indian Journal of Anaesthesia;Jul/Aug2014, Vol. 58 Issue 4, p493 

    The article discusses a case study of a 65-year-old female patient with Osler-Weber Rendu's syndrome or hereditary haemorrhagic telangiectasia (HHT). Details of the medical conditions of the patient are presented. The challenges posed by the disease to the anaesthetic management of the patient...

  • Antioxidants can prevent photoreceptor degeneration.  // Journal of Clinical Investigation;Mar2009, Vol. 119 Issue 3, p423 

    The article reports on a study which has revealed that mice lacking VLDL receptor (VLDLR) have a retinal phenotype similar to that observed in individuals with either a number of disease states, including macular telangiectasia (MacTel) and retinal angiomatous proliferation (RAP). It has also...

  • Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Govani, Fatima S.; Shovlin, Claire L. // European Journal of Human Genetics;Jul2009, Vol. 17 Issue 7, p860 

    The autosomal-dominant trait hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5–8000 people. Genes mutated in HHT (most commonly for endoglin or activin receptor-like kinase (ALK1)) encode proteins that modulate transforming growth factor (TGF)-β superfamily signalling in...

  • Understanding IPL. Krader, Cheryl Guttman // Cosmetic Surgery Times;Oct2011, Vol. 14 Issue 9, p32 

    The article presents a study on the safety and effectiveness of matching the intense pulsed light (IPL) device with a pulsed dye laser (PDL) in the treatment of facial telangiectasias. Doctor Emil Tanghetti, states that IPL device is an attractive technology to practitioners for reasons of cost...

  • Hemorrhagic Hereditary Telangiectasia (Rendu-Osler Disease) and Infectious Diseases: An Underestimated Association. Dupuis-Girod, Sophie; Giraud, Sophie; Decullier, Evelyne; Lesca, Gaetan; Cottin, Vincent; Faure, Frédéric; Merrot, Olivier; Saurin, Jean-Christophe; Cordier, Jean-François; Plauchu, Henri // Clinical Infectious Diseases;3/15/2007, Vol. 44 Issue 6, p841 

    Among 353 patients with hereditary hemorrhagic telangiectasia retrospectively analyzed during the period 1985-2005, we identified 67 cases of severe infection that affected 48 patients (13.6%). Extracerebral infections accounted for 67% of all infections, and most involved Staphylococcus aureus...

  • Osler-Weber-Rendu syndrome. Bates, M. C.; Almehmi, A. // Heart;Dec2005, Vol. 91 Issue 12, p1572 

    The article presents a case study of Osler-Weber- Rendu syndrome. The patient was a 54-year old white woman. She was admitted with a 10-year history of progressive dyspnoea and exertional hypoxia. The typical clinical stigmata of periungual erythema/telangiectasias and telangiectasias of both...

  • Long Term Result of Intravitreal Bevacizumab in a Patient Newly Transformed to Proliferative Macular Telangiectasia Type 2. Ozkaya, Abdullah; Alkin, Zeynep; Karakucuk, Yalcin; Yazici, Ahmet Taylan; Demirok, Ahmet // Middle East African Journal of Ophthalmology;Oct-Dec2013, Vol. 20 Issue 4, p360 

    The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics